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are expressed as cost per quality adjusted life year (QALY) gained. Perspective is
that of the national health system (NHS). Benefits and costs were discounted with
3% per year. RESULTS: Over the 3 year analysis period, 2.12 life years per patient
were achieved with TA TAVI, 2.31 with TF TAVI and 1.51 with conservative medical
care, representing. 1.24, 1.38 and 0.74 QALYs, respectively. Cumulative direct costs
were predicted to amount to €37,311 and €35,689 with TA and TF TAVI, respectively
and to €23,103 with conservative care. Cost/QALY gained was €28,003 for TA TAVI
and €19,499 for TF TAVI, both ratios remaining well below the accepted willing-
ness-to-pay threshold for Spain. The substantial cost of the TAVI procedure was
largely offset over time mainly by savings related to prevented hospital readmis-
sions for cardiac reasons. Sensitivity analyses indicated these findings to be robust.
CONCLUSIONS: Compared to conservative management, TAVI is a life-saving and
cost-effective treatment for high-risk or inoperable patients with symptomatic
aortic valve stenosis in Spain.
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OBJECTIVES: The aim of this study was to combine clinical results from the RE-
VERSE study (Resynchronisation reverses Remodelling in Systolic Left Ventricular
Dysfunction) and costs associated with the addition of cardiac resynchronization
therapy (CRT) to optimal medical therapy (OMT) in patients with mild symptomatic
(NYHA I-II) or asymptomatic left ventricular dysfunction and markers of cardiac
dyssynchrony in Spain. METHODS: We developed a Markov model of CRT  OMT
(CRT-ON group) vs. OMT alone (CRT-OFF group) based on a retrospective cost-
effectiveness analysis. Raw data from the model was derived from literature and
expert opinion, reflecting clinical and economic consequences of patient’s man-
agement in Spain. Time horizon was 10 years, and costs were expressed in Euro
2010. Both costs and effects were discounted at 3% per annum. RESULTS: CRT-ON
group showed higher total costs than CRT-OFF, however patients with CRT reduced
94% the length of hospitalization in the ICU (0.006 vs. 0.091 days) and 34% in general
ward (0.705 vs. 1.076 days). Surviving patients with CRT-ON (88.2% vs. 77.5%) re-
mained in slighter functional class longer and they achieved an improvement of 0.9
life years (LYGs) and 0.77 years quality-adjusted life years (QALYs). In terms of cost
per LYGs, the results were €40,782 (5 years) and €18,431 (10 years), and in terms of
costs per QALYs gained were €39,800 and €21,500 at 5 and 10 years respectively.
Probabilistic sensitivity analysis showed that the probability of CRT-ON was cost-
effective is 65.54% at 10 years. CONCLUSIONS: The use of CRT added to OMT
represents an efficient use of resources in patients suffering from heart failure in
NYHA functional class I and II, with cost-effectiveness ratios below the Spanish
threshold at 10 years.
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OBJECTIVES: Case detection is key to identifying leprosy disease early in its devel-
opment for more effective prevention of progression to permanent disability. The
study evaluated the costs and cost-effectiveness of three leprosy case detection
methods in Nigeria’s north-eastern states of Adamawa and Gombe; namely Rapid
Village Survey (RVS), Household Contact Examination (HCE) and Traditional Heal-
er’s (THs) incentive approach METHODS: The study was cross-sectional and ex-
plorative, undertaken in routine practice setting, targeting endemic and non-en-
demic communities selected randomly. Primary and secondary data were collected
from routine practice records and the Nigerian Leprosy Elimination Programme
2009. All costs were measured from both providers’ and patients’ perspectives.
Effectiveness was measured as new cases detected and outcome expressed as cost
per case detected. Incremental approach, using routine passive case detection
method as a reference was used to estimate the costs and effects by comparing
each method against the routine practise; to measure additional cost per new case
detected, as incremental cost-effectiveness ratio (ICER). Univariate sensitivity
analysis was carried out to evaluate uncertainties around the ICER. All costs were
converted to US Dollars at the 2010 exchange rate. RESULTS:HCE generated a total
of $2416 at the lowest rate of $142 per additional case detected at all contact levels,
as the most cost-effective method while the RVS was dominated by THs method
which generated a total of $4447 at $193 per new case detected.Variation of diag-
nostic accuracy and subsistent wage for valuing unpaid time did not significantly
change the results. CONCLUSIONS: From both perspectives and at all contact lev-
els, the Household Contact Examination, complementing routine practice demon-
strated the most cost-effective approach to identifying new leprosy cases for effec-
tive prevention and control of leprosy in Nigeria. It will be necessary to carry out
implementation studies to establish the feasibility and acceptability of the method
in other leprosy areas.
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OBJECTIVES: To determine the cost-effectiveness of measuring glycated hemoglo-
bin with A1CNow ® compared with standard exam (SE) for DM2 patients, from the
Brazilian Private Healthcare System perspective. METHODS: The study was a cost-
effectiveness analysis based on Markov modeling to estimate costs and conse-
quences of treatments. Epidemiological and efficacy data derived from a critical
appraisal of the scientific literature. Only direct medical costs were considered. If
available, costs of clinical events (CE) were obtained from burden of disease stud-
ies. If not, Brazilian official guidelines were obtained to determine the resources
used to treat the CE. Drugs, hospital daily admission rates, procedures and labora-
tory tests unit costs were obtained from Brazilian official databases. Costs and
benefits were discounted at 5% yearly. Outcomes were expressed as CE avoided.
Probability sensitivity analysis (PSA) was conducted to assess model robustness.
Life time horizon was analyzed. RESULTS: Through the systematic review of the
literature the studies were selected to form the body of clinical data for the analy-
ses. The systematic review showed that although the absence of studies directly
evaluating the impact of A1CNow on cardiovascular events, their favorable influ-
ence on cardiovascular disease intermediate markers suggests that A1CNow may
have clinically relevant effect in patients at risk. The analysis showed higher clin-
ical benefits and lower costs for A1CNow. Considering 100 patients, 99.8 and 146.1
CE happen in A1CNow and SE arms, respectively. The average time-horizon cost
per patient was R$25,444(€11,108) and R$29,278(€12,782) for A1CNow and SE, re-
spectively, showing the dominance of A1CNow compared to SE. PSA demonstrated
that in 95.3% of the simulations A1CNow was dominant (more effective with lower
cost) compared to SE. CONCLUSIONS: Our study demonstrated that A1CNow have
clinically relevant effect in reducing CE being dominant for monitoring of glycated
hemoglobin in DM2 patients. PSA confirmed this determinist result.
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OBJECTIVES: Atrial Fibrillation (AF) is the most common arrhythmia among the
elderly. It has dire consequences, stroke being the most catastrophic. Its burden is
highly significant; changing demographics lead to more patients impacted. Man-
aging AF encompasses arrhythmia control and stroke prevention – with new tech-
nologies being developed for both. For Paroxysmal AF (PAF) – which terminates
spontaneously within 7 days – electrical Pulmonary Vein Isolation (PVI) has ad-
vanced as the cornerstone treatment in patients unresponsive to pharmaceuticals.
PAF accounts for 75% of patients, and half are medicated with sub-optimal out-
comes. We sought to evaluate the cost-effectiveness of PVI when using a new
balloon-based catheter using cooling energy for lesion creation (Arctic Front,
Medtronic). METHODS: A Markov Microsimulation Model compared treatment
with Arctic Front vs. conventional drugs. STOP-AF Pivotal Trial Data were used to
estimate PVI efficacy and complication rates. A literature review identified data for
long-term PVI and drug therapy outcomes. The model incorporated Arctic Front
specific complication rates (e.g. stroke, tamponade and phrenic nerve paralysis)
and drug toxicities and impact on stroke risk was included. Utility weights were
assigned for various health states. and a range of time horizons was used, with a UK
perspective adopted for costs and benefits. One-way and probabilistic sensitivity
analyses were undertaken. RESULTS: Depending on the time horizon, the ICER
ranged from £3,200/QALY to £15,700/QALY gained. Results were sensitive to as-
sumptions regarding long-term outcomes and the quality of life benefit of remain-
ing free of PAF. CONCLUSIONS: PVI can be highly cost-effective in treating PAF – a
highly prevalent and burdensome disease. Results are consistent with similar tech-
nology economic evaluations, and reinforce the evidence base for PVI as a cost-
effective therapy for PAF.
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OBJECTIVES: The main purpose of this study was to conduct an economic evalua-
tion of Primovist enhanced MRI (PV-MRI) compared to extracellular contrast-me-
dia-enhanced MRI (ECC-MRI) in patients suffering from liver metastases of colo-
rectal origin in Spain. METHODS: An analytic model previously implemented in
three European countries (Germany, Italy and Sweden) was adapted in Spain to
estimate all aggregated costs of both diagnosis options compared. Probabilities of
needing further imaging and of needing surgical plans modification or confirma-
tion were adjusted by Spanish clinical experts (surgeons and radiologists). Con-
trasts cost was estimated from PTR (weighting the different EECs prices for sales in
Spain for this option), and tests (MRI and CT) and different surgery procedures (high
or low risk, modification or confirmation of surgical plans, etc.) costs were ex-
tracted from official fees of different Spanish Autonomous Communities (CCAA).
RESULTS: PV-MRI was associated with a reduced need for extra imaging tests (6%
vs. 9%). Taking into account the costs of diagnosis tests and surgery procedures
(including modification of surgical plans during intervention), PV-MRI option was a
cost-neutral strategy, with total costs similar to ECC-MRI (576 € vs. € 578, PV-MRI vs
ECC-MRI respectively). CONCLUSIONS: Additional costs associated with colorectal
liver metastases diagnosis with PV-MRI regarding to ECC-MRI are offset by lower
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